NOVEL CELLULOSE COPOLYMERS FOR BIOMEDICAL APPLICATIONS

用于生物医学应用的新型纤维素共聚物

• 批准号: 6288252
• 负责人: MANSSUR YALPANI
• 金额: $ 11.63万
• 依托单位: CARBOMER, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2001-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6288252
• 关键词: N acetylglucosamine; biomaterial compatibility; biomaterial development /preparation; biomaterial evaluation; cellulose; copolymer; glucosamine; glucose

We are proposing the development of new biocompatible biomaterials for biomedical uses and specifically for the preparation of separation devices. The new biomaterials can be readily derived with a high yielding, cost-effective proprietary process that also permits the preparation of a range of different compositions. Preliminary data from pilot studies indicate that the new biomaterials constitute promising membrane materials. PROPOSED COMMERCIAL APPLICATIONS: Significant morbidity and mortality remain in hemodialysis patients due to the deleterious consequences of blood-membrane interactions. New efficacious hemodialysis membranes would constitute a major milestone in this field. The development of immunoadsorbents usable with whole blood should offer the potential for making significant improvements in extracorporeal immunoadsorption procedures. In contrast to traditional chromatographic media, these hemocompatible matrices could be used without requiring the previous step of the separation of blood cells and plasma.

我们建议开发新的生物相容性生物材料用于生物医学用途，特别是用于制备分离装置。新的生物材料可以很容易地用高产，具有成本效益的专有工艺获得，该工艺还允许制备一系列不同的组合物。初步研究的初步数据表明，新的生物材料构成有前途的膜材料。拟议的商业应用：血液透析患者由于血-膜相互作用的有害后果，仍然存在显著的发病率和死亡率。新的有效的血液透析膜将构成这一领域的一个重要里程碑。可用于全血的免疫吸附剂的开发应提供在体外免疫吸附程序中进行显著改进的潜力。与传统的色谱介质相比，这些血液相容性基质可以在不需要分离血细胞和血浆的先前步骤的情况下使用。